腾讯及天士力入股干细胞治疗公司跃赛生物

天眼查04-22

天眼查App显示，近日，上海跃赛生物科技有限公司发生工商变更，新增股东腾讯旗下广西腾讯创业投资有限公司、天士力（600535）旗下绍兴天士力生物医药产业股权投资基金合伙企业（有限合伙）、浦东创投旗下上海浦东天使创业投资合伙企业（有限合伙），同时，公司注册资本由约337万人民币增至约386万人民币。上海跃赛生物科技有限公司成立于2021年6月，法定代表人为高琴琴，经营范围含细胞技术研发和应用、医学...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2429990842?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-22 13:48","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2429990842","market":"hk","top_or_hot":-1,"title":"腾讯及天士力入股干细胞治疗公司跃赛生物","media":"天眼查","content":"<div>\n<p>天眼查App显示，近日，上海跃赛生物科技有限公司发生工商变更，新增股东腾讯旗下广西腾讯创业投资有限公司、天士力（600535）旗下绍兴天士力生物医药产业股权投资基金合伙企业（有限合伙）、浦东创投旗下上海浦东天使创业投资合伙企业（有限合伙），同时，公司注册资本由约337万人民币增至约386万人民币。上海跃赛生物科技有限公司成立于2021年6月，法定代表人为高琴琴，经营范围含细胞技术研发和应用、医学...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422135648879fb5d2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>腾讯及天士力入股干细胞治疗公司跃赛生物</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n腾讯及天士力入股干细胞治疗公司跃赛生物\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-22 13:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422135648879fb5d2&s=b><strong>天眼查</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>天眼查App显示，近日，上海跃赛生物科技有限公司发生工商变更，新增股东腾讯旗下广西腾讯创业投资有限公司、天士力（600535）旗下绍兴天士力生物医药产业股权投资基金合伙企业（有限合伙）、浦东创投旗下上海浦东天使创业投资合伙企业（有限合伙），同时，公司注册资本由约337万人民币增至约386万人民币。上海跃赛生物科技有限公司成立于2021年6月，法定代表人为高琴琴，经营范围含细胞技术研发和应用、医学...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422135648879fb5d2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0163747925.USD","symbol_name":"EASTSPRING INVESTMENTS ASIAN EQUITY A ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422135648879fb5d2&s=b","article_id":"2429990842","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422135648879fb5d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2429990842","pubTimestamp":1713764892,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"天眼查App显示，近日，上海跃赛生物科技有限公司发生工商变更，新增股东腾讯旗下广西腾讯创业投资有限公司、天士力（600535）旗下绍兴天士力生物医药产业股权投资基金合伙企业（有限合伙）、浦东创投旗下上海浦东天使创业投资合伙企业（有限合伙），同时，公司注册资本由约337万人民币增至约386万人民币。上海跃赛生物科技有限公司成立于2021年6月，法定代表人为高琴琴，经营范围含细胞技术研发和应用、医学研究和试验发展、企业管理、企业管理咨询等。公开信息显示，跃赛生物一直致力于开发新一代基于人多能干细胞技术的细胞治疗药物，在研管线覆盖帕金森病和其他神经退行性疾病。不久前，该公司宣布完成超亿元A轮融资。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"80700":"腾讯控股-R","600535":"天士力","LU0163747925.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY A ACC","BK1609":"ChatGPT概念","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0128522157.USD":"TEMPLETON ASIAN GROWTH \"A\" ACC","BK1526":"科网股","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU0348788117.USD":"ALLIANZ EMERGING ASIA EQUITY \"A\" (USD) INC","LU0084288322.USD":"Natixis Asia Equity RD USD","LU0348814723.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"A\" (USD) INC  NC","00700":"腾讯控股","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","LU0054450605.USD":"HSBC GIF GLOBAL EMERGING MARKTS EQ \"AD\" INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0051755006.USD":"摩根大通中国A (dist)","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0315178854.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"A\" ACC","LU0181495838.USD":"施罗德新兴亚洲A Acc","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0029875118.USD":"TEMPLETON ASIAN GROWTH \"A\" INC","LU0029874905.USD":"TEMPLETON EMERGING MARKETS \"A\" INC","BK1610":"ETF&股票定投概念","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD","BK1586":"云计算","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0052750758.USD":"富兰克林中国基金A Acc","BK1095":"互动媒体与服务","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0173614495.USD":"富达中国焦点A","LU0128522744.USD":"TEMPLETON EMERGING MARKETS \"A\" ACC","LU0359201612.USD":"贝莱德中国基金A2","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0229945570.USD":"TEMPLETON BRIC \"A\" (USD) ACC","IE00BF5LJ272.USD":"Legg Mason Martin Currie - Global Emerging Markets A Acc USD","LU0228367735.SGD":"Eastspring Investments - Asian Equity Fund AS SGD","LU0048580855.USD":"富达大中华区A","BK1608":"元宇宙概念","BK1502":"双十一","LU0320764755.SGD":"FTIF - Templeton Asian Growth A Acc SGD","LU0293314216.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"A\" (USD) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","IE0032431581.USD":"PINEBRIDGE GREATER CHINA EQUITY \"A\" (USD) ACC","BK1531":"手游股","IE0034224299.USD":"PINEBRIDGE ASIA EX JAPAN EQUITY \"A\" (USD) ACC","LU0080751232.USD":"富达环球多元动力基金A","LU0320764243.SGD":"FTIF - Templeton Emerging Markets A Acc SGD","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0348805143.USD":"ALLIANZ ENHANCED ALL CHINA EQUITY \"A\" (USD) INC","LU0048597586.USD":"富达亚洲焦点A"},"translate_title":"Tencent and Tasly invest in stem cell therapy company Yuesai Biotech","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"80700":0.6,"600535":0.9,"00700":1},"content_text":"天眼查App显示，近日，上海跃赛生物科技有限公司发生工商变更，新增股东腾讯旗下广西腾讯创业投资有限公司、天士力（600535）旗下绍兴天士力生物医药产业股权投资基金合伙企业（有限合伙）、浦东创投旗下上海浦东天使创业投资合伙企业（有限合伙），同时，公司注册资本由约337万人民币增至约386万人民币。上海跃赛生物科技有限公司成立于2021年6月，法定代表人为高琴琴，经营范围含细胞技术研发和应用、医学研究和试验发展、企业管理、企业管理咨询等。公开信息显示，跃赛生物一直致力于开发新一代基于人多能干细胞技术的细胞治疗药物，在研管线覆盖帕金森病和其他神经退行性疾病。不久前，该公司宣布完成超亿元A轮融资。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429990842"}